SCHEMBL64529

SCHEMBL64529

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCCOc2ccccc2)c(O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
CXCR3 P49682 4/20 0.36
TSHR P16473 2/20 0.36
NPC1 O15118 6/20 0.36
RAB9A P51151 6/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 1/20 0.36
CHRNA7 P36544 1/20 0.36
CYP2C9 P11712 1/20 0.36
TYK2 P29597 1/20 0.35
PKM P14618 1/20 0.35
EPHX2 P34913 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
POLB P06746 1/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
RECQL P46063 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62742 0.90 CYP2C9 (0.38) CYP2C9
SCHEMBL63505 0.88 L3MBTL1 (0.39) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL53142 0.88 CYP2C9 (0.45) ALDH1A1NPC1RAB9ACYP2C9PKM
SCHEMBL63890 0.86 CYP2C9 (0.36) SMN1; SMN2CYP2C9POLB
SCHEMBL64273 0.84 CYP2C9 (0.39) ALDH1A1TSHRNPC1HPGDCYP2C9
SCHEMBL63901 0.83 CYP2C9 (0.38) NPC1RAB9ASMN1; SMN2CYP2C9MAPT
SCHEMBL62746 0.82 ABCB1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2CYP2C9
SCHEMBL52278 0.82 CYP2C9 (0.45) NPC1RAB9ACYP2C9MEN1KMT2A
SCHEMBL63534 0.82 HTT (0.40) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL63538 0.82 CYP2C9 (0.46) ALDH1A1HPGDCYP2C9EPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ALDH1A1 539/4885CXCR3 2131/4885TSHR 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.